1. Home
  2. MNDY vs PRAX Comparison

MNDY vs PRAX Comparison

Compare MNDY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo monday.com Ltd.

MNDY

monday.com Ltd.

N/A

Current Price

$75.72

Market Cap

7.4B

Sector

Technology

ML Signal

N/A

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$301.75

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MNDY
PRAX
Founded
2012
2015
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
9.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
MNDY
PRAX
Price
$75.72
$301.75
Analyst Decision
Buy
Strong Buy
Analyst Count
25
15
Target Price
$174.92
$572.13
AVG Volume (30 Days)
3.0M
328.9K
Earning Date
01-01-0001
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$20.70
N/A
Revenue Next Year
$16.48
$6,395.88
P/E Ratio
$34.38
N/A
Revenue Growth
N/A
N/A
52 Week Low
$68.68
$26.70
52 Week High
$316.98
$354.87

Technical Indicators

Market Signals
Indicator
MNDY
PRAX
Relative Strength Index (RSI) 36.83 39.85
Support Level $68.80 $290.36
Resistance Level $79.30 $322.32
Average True Range (ATR) 4.09 17.69
MACD 2.68 -5.16
Stochastic Oscillator 53.26 14.99

Price Performance

Historical Comparison
MNDY
PRAX

About MNDY monday.com Ltd.

Monday.com is a work management platform allowing for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2024, the company had over 245,000 customers.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: